Search tips
Search criteria 


Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
AAPS PharmSciTech. 2005 June; 6(2): E223–E230.
Published online 2005 September 30. doi:  10.1208/pt060232
PMCID: PMC2750535

Devitrification of amorphous celecoxib


The purpose of this research was to analyze the devitrification of amorphous celecoxib (CEL) in the presence of different stressors (temperature, pressure, and/or humidity) encountered during processing of solid dosage forms. Amorphous CEL was prepared in situ in the analytical instruments, as well as in laboratory, by quench-cooling of melt process, and analyzed by dynamic mechanical thermal analysis, differential scanning calorimetry, microscopy, and Fourier-transform infrared spectroscopy. Amorphous CEL prepared in situ in the analytical instruments was resistant to crystallization under the influence of temperature and/or pressure, because of its protection from the external environment during preparation. These samples exhibited structural relaxation during annealing at 25°C/0% relative humidity (RH) for 16 hours. Generation of amorphous CEL in the laboratory resulted in partially crystalline samples, because of exposure to environmental temperature and humidity, resulting in incomplete vitrification. Subjection to thermal stress favored crystallization of amorphous CEL into metastable polymorphic forms, which were not obtained by solvent recrystallization approach. Temperature and humidity were identified as the major factors promoting devitrification of amorphous CEL, leading to loss of solubility advantage. Exposure to International Conference on Harmonization-specified accelerated stability storage conditions (40°C/75% RH) resulted in complete devitrification of amorphous CEL within 15 days. The phase-transformation process of amorphous CEL along the temperature scale was examined visually, as well as spectrally. This propensity for devitrification of amorphous CEL seemed to depend on the strength of differential molecular interactions between the amorphous and crystalline form.

KeyWords: amorphous, crystallization, processing, stress, celecoxib

Full Text

The Full Text of this article is available as a PDF (4.2M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Kaushal AM, Gupta P, Bansal AK. Amorphous drug delivery systems: Molecular aspects, design and performance. Crit Rev Ther Drug Carrier Syst. 2004;21:133–193. doi: 10.1615/CritRevTherDrugCarrierSyst.v21.i3.10. [PubMed] [Cross Ref]
2. Tang XC, Pikal MJ, Taylor LS. A spectroscopic investigation of hydrogen bond patterns in crystalline and amorphous phases in dihydropyridine calcium channel blockers. Pharm Res. 2002;19:477–483. doi: 10.1023/A:1015147729564. [PubMed] [Cross Ref]
3. Brittain HG. Effects of mechanical processing on phase composition. J Pharm Sci. 2002;91:1573–1580. doi: 10.1002/jps.10115. [PubMed] [Cross Ref]
4. York P. Solid-state properties of powders in the formulation and processing of solid dosage forms. Int J Pharm. 1983;14:1–28. doi: 10.1016/0378-5173(83)90111-4. [Cross Ref]
5. Sjokvist E, Nystrom C. Physicochemical aspects of drug release. XI. Tableting properties of solid dispersions, using xylitol as carrier material. Int J Pharm. 1991;67:139–153. doi: 10.1016/0378-5173(91)90426-O. [Cross Ref]
6. Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. Comparison of the mechanical properties of the crystalline and amorphous forms of a drug substance. Int J Pharm. 2002;241:73–85. doi: 10.1016/S0378-5173(02)00133-3. [PubMed] [Cross Ref]
7. Chawla G, Gupta P, Thilagavathi R, Chakraborti AK, Bansal AK. Characterization of solid-state forms of celecoxib. Eur J Pharm Sci. 2003;20:305–317. doi: 10.1016/S0928-0987(03)00201-X. [PubMed] [Cross Ref]
8. Gupta P, Chawla G, Bansal AK. Physical stability and solubility advantage from amorphous celexocib: The role of thermodynamic quantities and molecular mobility. Mol Pharm. 2004;1:406–413. doi: 10.1021/mp049938f. [PubMed] [Cross Ref]
9. Kakumanu VK, Bansal AK. Enthalpy relaxation studies of celecoxib amorphous mixtures. Pharm Res. 2002;19:1873–1878. doi: 10.1023/A:1021453810624. [PubMed] [Cross Ref]
10. Gupta P, Kakumanu VK, Bansal AK. Stability and solubility of celecoxib-PVP amorphous dispersions: A molecular perspective. Pharm Res. 2004;21:1762–1769. doi: 10.1023/B:PHAM.0000045226.42859.b8. [PubMed] [Cross Ref]
11. Kararli TT, Hurlbut JB, Needham TE. Glass-rubber transitions of cellulosic polymers by dynamic mechanical analysis. J Pharm Sci. 1990;79:845–848. doi: 10.1002/jps.2600790922. [PubMed] [Cross Ref]
12. Craig DQM, Johnson FA. Pharmaceutical applications of dynamic mechanical thermal analysis. Thermochim Acta. 1995;248:97–115. doi: 10.1016/0040-6031(94)01888-N. [Cross Ref]
13. Ford JL, Timmins P. Pharmaceutical Thermal Analysis: Techniques and Applications. Chichester, UK: Ellis Horwood Ltd; 1989.
14. Riesen R, Schawe J. The glass transition temperature measured by different TA techniques. Part 1: Overview. User Com Mettler Toledo. 2003;1:1–4.
15. Neilson LE. Mechanical Properties of Polymers and Composites. New York: Marcel Dekker; 1974. Mechanical tests and polymer transitions; Elastic moduli; and Dynamic mechanical properties; pp. 11–17.
16. Riesen R, Schawe J. The glass transition temperature measured by different TA techniques. Part 2: Determination of glass transition temperatures. User Com Mettler Toledo. 2003;2:1–5.
17. Foreman J, Sauerbrunn SR, Marcozzi CL. Exploring the sensitivity of thermal analysis techniques to the glass transition. TA Instruments: Thermal Analysis & Rheology, Application note number TA-082B,
18. Omelczuk MO, McGinity JW. The influence of polymer glass transition temperature and molecular weight on drug release from tablets containing poly(DL-lactic acid) Pharm Res. 1992;9:26–32. doi: 10.1023/A:1018967424392. [PubMed] [Cross Ref]
19. Miller DP, Pablo JJ, Corti H. Thermophysical properties of trehalose and its concentrated aqueous solutions. Pharm. Res. 1997;14:578–590. doi: 10.1023/A:1012192725996. [PubMed] [Cross Ref]
20. Hodge IM. Enthalpy relaxation and recovery in amorphous materials. J Non-Cryst Solids. 1994;169:211–266. doi: 10.1016/0022-3093(94)90321-2. [Cross Ref]
21. Ferro LJ, Miyake PJ. Polymorphic crystalline forms of celecoxib. 2001; WO 01/4222 A1.
22. Ostwald W. Studien uber die bildung und umwandlung fester korper. Zieitschrigt Fur Physikalische Chemi. 1897;22:289–330.
23. Slootmaekers B, Desseyn HO. Characterization of inter-and intramolecular hydrogen bonding in the solid state using variable-temperature IR spectroscopy. Appl Spectrosc. 1991;45:118–120. doi: 10.1366/0003702914337876. [Cross Ref]
24. Ediger MD, Angell CA, Nagel SR. Supercooled liquids and glasses. J Phys Chem. 1996;100:13200–13212. doi: 10.1021/jp953538d. [Cross Ref]
25. Hancock BC, Shamblin SL. Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetry. Thermochim Acta. 2001;380:95–107.
26. Yu L. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Del Rev. 2001;48:27–42. doi: 10.1016/S0169-409X(01)00098-9. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists